← Leaderboards
Burns C Blaxall
University Of Rochester
$8,103,252
Attributed
$8,580,499
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2008–18$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$8,580,499 · 7
By mechanism
R01$8,134,984 · 6
S10$445,515 · 1
Top collaborators
- Prasad Devarajan2 shared
Most similar at University Of Rochester
Same institution · by research overlap
- Wang Min$16,059,498
- Alan V. Smrcka$18,253,223
- Bradford C Berk$28,468,508
- Sanjay B. Maggirwar$21,478,048
- Jenna Mae Tabor-Godwin$159,168
Others in their field
Top investigators on “Functional Disorder”
- Randall J Bateman · Washington University$164,791,794
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- David Heimbrook · Leidos Biomedical Research, Inc.$127,725,513
- Ed Lein · Allen Institute$92,850,604
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
- John M Lachin · George Washington University$85,958,868
Research focus
Functional DisorderTissuesPathologicCardiacIn VivoHeart FailureOutcome ForecastCardiac MyocytesSignal TransductionBaseHeartGeneticFibrosisPlayMouse ModelCellsAblationMembraneChronicAcuteResponsePhosphotransferasesInjuryReperfusion Injury
Grant awards (23)
Targeting fibronectin in cardiac remodeling and fibrosis$390,000
R01 · FY2018 · HL · contact PI
Targeting Gbg-GRK2 signaling in fibrotic remodeling$390,000
R01 · FY2018 · HL · contact PI
Small molecule targeting of MLK3 for heart failure$390,000
R01 · FY2018 · HL · contact PI
Targeting pathologic G-protein signaling in cardiac and kidney fibrosis$470,895
R01 · FY2017 · HL · contact PI
Small molecule targeting of MLK3 for heart failure$390,000
R01 · FY2017 · HL · contact PI
Targeting fibronectin in cardiac remodeling and fibrosis$390,000
R01 · FY2017 · HL · contact PI
Targeting Gbg-GRK2 signaling in fibrotic remodeling$390,000
R01 · FY2017 · HL · contact PI
Targeting pathologic G-protein signaling in cardiac and kidney fibrosis$483,600
R01 · FY2016 · HL · contact PI
Targeting Gbg-GRK2 signaling in fibrotic remodeling$390,000
R01 · FY2016 · HL · contact PI
Targeting fibronectin in cardiac remodeling and fibrosis$390,000
R01 · FY2016 · HL · contact PI
Small molecule targeting of MLK3 for heart failure$390,000
R01 · FY2016 · HL · contact PI
Targeting of B-AR/GBy signaling in the heart with small molecules$360,499
R01 · FY2013 · HL · contact PI
Targeting of B-AR/GBy signaling in the heart with small molecules$382,388
R01 · FY2012 · HL · contact PI
A Role for Mena in the Heart$247,104
R01 · FY2012 · HL · contact PI
A Role for Mena in the Heart$134,046
R01 · FY2012 · HL · contact PI
Targeting of B-AR/GBy signaling in the heart with small molecules$385,313
R01 · FY2011 · HL · contact PI
A Role for Mena in the Heart$385,000
R01 · FY2011 · HL · contact PI
A Role for Mena in the Heart$385,000
R01 · FY2010 · HL · contact PI
Targeting of B-AR/GBy signaling in the heart with small molecules$383,125
R01 · FY2010 · HL · contact PI
VisualSonics Vevo 2100$445,515
S10 · FY2009 · RR · contact PI
A Role for Mena in the Heart$385,000
R01 · FY2009 · HL · contact PI
A Role for Mena in the Heart$238,014
R01 · FY2009 · HL · contact PI
A Role for Mena in the Heart$385,000
R01 · FY2008 · HL · contact PI